Novolog Innolet is a drug owned by Novo Nordisk Inc. It is protected by 6 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 21, 2021. Details of Novolog Innolet's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
USRE41956 (Pediatric) | Dose setting limiter |
Jul, 2021
(4 years ago) |
Expired
|
| USRE41956 | Dose setting limiter |
Jan, 2021
(5 years ago) |
Expired
|
|
US5866538 (Pediatric) | Insulin preparations containing NaCl |
Dec, 2017
(8 years ago) |
Expired
|
| US5866538 | Insulin preparations containing NaCl |
Jun, 2017
(8 years ago) |
Expired
|
|
US5618913 (Pediatric) | Insulin analogues |
Dec, 2014
(11 years ago) |
Expired
|
| US5618913 | Insulin analogues |
Jun, 2014
(11 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Novolog Innolet's patents.
Latest Legal Activities on Novolog Innolet's Patents
Given below is the list of recent legal activities going on the following patents of Novolog Innolet.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 23 Nov, 2010 | USRE41956 |
| Email Notification | 04 Nov, 2010 | USRE41956 |
| Issue Notification Mailed | 03 Nov, 2010 | USRE41956 |
| Receipt into Pubs | 18 Oct, 2010 | USRE41956 |
| Dispatch to FDC | 15 Oct, 2010 | USRE41956 |
| Application Is Considered Ready for Issue | 14 Oct, 2010 | USRE41956 |
| Issue Fee Payment Received | 13 Oct, 2010 | USRE41956 |
| Issue Fee Payment Verified | 13 Oct, 2010 | USRE41956 |
| Printer Rush- No mailing | 01 Sep, 2010 | USRE41956 |
| Pubs Case Remand to TC | 17 Aug, 2010 | USRE41956 |
US patents provide insights into the exclusivity only within the United States, but
Novolog Innolet is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Novolog Innolet's family patents as well as insights into
ongoing legal events
on those patents.
Novolog Innolet's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Novolog Innolet's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 21, 2021 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Novolog Innolet Generics:
There are no approved generic versions for Novolog Innolet as of now.
Alternative Brands for Novolog Innolet
There are several other brand drugs using the same active ingredient (Insulin Aspart Recombinant) as Novolog Innolet. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc |
|
About Novolog Innolet
Novolog Innolet is a drug owned by Novo Nordisk Inc. Novolog Innolet uses Insulin Aspart Recombinant as an active ingredient. Novolog Innolet was launched by Novo Nordisk in 2013.
Approval Date:
Novolog Innolet was approved by FDA for market use on 31 October, 2013.
Active Ingredient:
Novolog Innolet uses Insulin Aspart Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Aspart Recombinant ingredient
Dosage:
Novolog Innolet is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 300 UNITS/3ML (100 UNITS/ML) | INJECTABLE | Discontinued | SUBCUTANEOUS |